Peregrine Pharmaceuticals (Nasdaq: PPHM) announced that three data presentations will discuss the immune-oncology and anti-viral potential of phosphatidylserine-targeting antibodies. Shares of the biopharmaceutical soared 51 cents to $2.42.
Peregrine's Immunotherapy Data To Be Presented
March 05, 2014 at 12:15 PM EST
